ZIOP ZIOPHARM Oncology Inc

5.73
+0.02  (+0%)
Previous Close 5.71
Open 5.71
Price To Book 12.46
Market Cap 930,520,451
Shares 162,394,494
Volume 745,709
Short Ratio
Av. Daily Volume 1,951,691

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 pivotal trial plans on hold due to Chemistry and Manufacturing Control (CMC) issues.
Ad-RTS-hIL-12 + veledimex
Glioblastoma multiforme (GBM)
Phase 1 completion of enrolment of third cohort announced June 26, 2019. Further data due in 2019.
Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO (nivolumab)
Refractory glioblastoma multiforme (GBM)
Phase 1 ongoing.
Ad-RTS-hIL-12 + veledimex
Brain cancer
Phase 1 ongoing.
CD33-specific CAR+ T
Acute Myeloid Leukemia (AML)
Phase 1 trial to begin dosing mid-2019.
Sleeping beauty - TCR-T cell therapy
Solid tumors
Phase 1 data at ASCO June 2019.
Ad-RTS-hIL-12
recurrent glioblastoma (rGBM)
Phase 2 initiation announced June 27, 2019.
Ad-RTS-hIL-12 plus veledimex plus Libtayo
Refractory glioblastoma multiforme (GBM)

Latest News

  1. Ziopharm Oncology Names NCI’s Dr. Drew Deniger to Direct TCR-T Cell Therapy Program
  2. Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo® (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma
  3. Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivolumab) Phase 1 Combination Trial in Brain Cancer
  4. ZIOPHARM Oncology (NASDAQ:ZIOP) Shareholders Have Enjoyed A 21% Share Price Gain
  5. Ziopharm Oncology Appoints Heidi Hagen to Board of Directors
  6. Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI
  7. Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
  8. The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation
  9. Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform
  10. Ziopharm Oncology Presentation at the Jefferies 2019 Global Healthcare Conference to be Webcast
  11. Edited Transcript of ZIOP earnings conference call or presentation 8-May-19 8:30pm GMT
  12. Ziopharm: 1Q Earnings Snapshot
  13. Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines
  14. ZIOPHARM Oncology, Inc. to Host Earnings Call
  15. Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019
  16. Edited Transcript of ZIOP earnings conference call or presentation 5-Mar-19 9:30pm GMT
  17. What Kind Of Shareholder Appears On The ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Shareholder Register?
  18. Ziopharma's Lead Asset Snags Fast Track Designation For Cancer Treatment
  19. Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma
  20. Ziopharm Oncology Inc (ZIOP) Q4 2018 Earnings Conference Call Transcript